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In Bordetella species, the BvgAS sensory transduction system mediates an alteration between the Bvg1 phase,
characterized by expression of adhesins and toxins, and the Bvg2 phase, characterized by the expression of
motility and coregulated phenotypes in Bordetella bronchiseptica and by the expression of vrg loci in Bordetella
pertussis. Since there is no known environmental or animal reservoir for B. pertussis, the causative agent of
whooping cough, it has been assumed that this phenotypic alteration must occur within the human host during
infection. Consistent with this hypothesis was the observation that a B. pertussis mutant, SK6, containing a
TnphoA insertion mutation in a Bvg-repressed gene (vrg6) was defective for tracheal and lung colonization in
a mouse model of respiratory infection (D. T. Beattie, R. Shahin, and J. Mekalanos, Infect. Immun. 60:571–577,
1992). This result was inconsistent, however, with the observation that a Bvg1 phase-locked B. bronchiseptica
mutant was indistinguishable from the wild type in its ability to establish a persistent respiratory infection in
rabbits and rats (P. A. Cotter and J. F. Miller, Infect. Immun. 62:3381–3390, 1994; B. J. Akerley, P. A. Cotter,
and J. F. Miller, Cell 80:611–620, 1995). To directly address the role of Bvg-mediated signal transduction in
B. pertussis pathogenesis, we constructed Bvg1 and Bvg2 phase-locked mutants and compared them with the
wild type for their ability to colonize the respiratory tracts of mice. Our results show that the Bvg1 phase of
B. pertussis is necessary and sufficient for respiratory infection. By constructing a strain with a deletion in the
bvgR regulatory locus, we also show that ectopic expression of Bvg2 phase phenotypes decreases the efficiency
of colonization, underscoring the importance of Bvg-mediated repression of gene expression in vivo. Finally, we
show that the virulence defect present in strain SK6 cannot be attributed to the vrg6 mutation. These data
contradict an in vivo role for the Bvg2 phase of B. pertussis.
All of the known protein virulence factors expressed by
Bordetella pertussis, the causative agent of whooping cough, are
positively regulated by the BvgAS sensory transduction system
(for reviews, see references 10, 32, and 33). When active,
BvgAS also represses a class of genes (vrg genes) and outer
membrane proteins (Vra proteins) of unknown function (16,
31). Hence, BvgAS mediates a phenotypic transition between
the Bvg1 phase, characterized by the expression of adhesins
and toxins, and the Bvg2 phase, characterized by the expres-
sion of vrg genes and Vra proteins. Transition from the Bvg1
phase to the Bvg2 phase has been termed phenotypic modu-
lation. Since B. pertussis has no known environmental or ani-
mal reservoir, it has been assumed that phenotypic modulation
must occur within the human host. Proposed roles for a switch
to the Bvg2 phase in vivo include evasion of antibodies di-
rected primarily against Bvg1 phase factors, tempering of dam-
age to host tissues as a result of decreased toxin expression,
increased transmission as a result of decreased adhesin expres-
sion, and a requirement for Bvg2 phase factors for the initial
interaction with the host or for surviving within host cells (6, 9,
17, 20, 25). Experimental evidence that B. pertussis switches to
the Bvg2 phase in vivo is limited to the observation that a
B. pertussis mutant containing a transposon insertion in a vrg
locus (vrg6) was defective for virulence in a mouse model (6).
Studies with Bordetella bronchiseptica, a very closely related
member of the Bordetella genus, contradict the hypothesis that
Bordetella switches to the Bvg2 phase in vivo. B. bronchiseptica
causes respiratory infections in a wide range of nonhuman
mammals, including dogs, pigs, rabbits, rats, and mice. It con-
tains a BvgAS sensory transduction system with 96% amino
acid identity to that of B. pertussis and expresses a nearly
identical set of Bvg-activated adhesins and toxins (4, 13). Stud-
ies with Bvg1 and Bvg2 phase-locked mutants showed that the
Bvg1 phase of B. bronchiseptica is necessary and sufficient for
respiratory infection, while the Bvg2 phase is required for
surviving nutrient limitation (1, 11). Moreover, failure to re-
press a Bvg2 phase phenotype (motility) was detrimental to
the development of infection, demonstrating the importance of
Bvg-mediated repression of gene expression in vivo (1). These
results led to the hypothesis that the role of BvgAS is to sense
whether the organism is within or outside a mammalian host.
A possible explanation for these apparently contradictory
results is that BvgAS plays different roles for these two species,
sensing whether the organism is within or outside a mamma-
lian host in the case of B. bronchiseptica and sensing specific
niches within the host in the case of B. pertussis. In support of
this hypothesis, the Bvg2 phases of these organisms appear to
differ dramatically (2, 6), and their BvgAS virulence control
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systems were recently shown to differ in their sensing capabil-
ities (19). Alternatively, we have proposed that BvgAS may have
originally evolved to serve the same purpose in both species,
sensing whether the organism is within or outside its host, but
that survival outside the host is no longer a significant part of
the life cycle for B. pertussis (19). Here we report an experi-
mental assessment of the role of BvgAS-mediated signal trans-
duction in B. pertussis pathogenesis as a means of testing these
opposing hypotheses. We constructed B. pertussis phase-locked
and ectopic expression mutants and compared them with the
wild type in a mouse model of respiratory infection. We also
addressed the role of vrg6 expression during infection by using
newly constructed vrg6 mutants and strains containing reporter
fusions designed to detect vrg6 expression in vivo. Our results in-
dicate that, like in B. bronchiseptica, the Bvg1 phase of B. per-
tussis is necessary and sufficient for respiratory infection and
that ectopic expression of Bvg-repressed phenotypes under
Bvg1 phase conditions is detrimental to the infection process.
We also demonstrate that the virulence defect in the original
vrg6 mutant, SK6, cannot be attributed to the vrg6 mutation.
MATERIALS AND METHODS
Bacterial strains and growth conditions. B. pertussis strains are described in
Table 1 and in the figure legends. B. pertussis SK6 and its parental strain, 18323,
were kindly provided by D. Beattie and R. Shahin, respectively. B. pertussis
strains were grown on BG agar (BBL, Becton Dickinson, Cockeysville, Md.)
supplemented with 15% defibrinated sheep blood (Mission Labs, Rosemead,
Calif.). Plates were incubated at 37°C for 72 to 96 h in loosely fitted screw-top jars
to provide a moist environment. When mid-log-phase cells were needed, B.
pertussis strains were grown in Stainer-Scholte (SS) medium (29) supplemented
with 1 g of heptakis (15) per liter at 37°C with constant shaking. To grow B.
pertussis under modulating (Bvg2 phase) conditions, MgSO4 (20 mM) and nic-
otinic acid (5 mM) were added to the culture medium. When appropriate,
antibiotics (Sigma Chemical Co., St. Louis, Mo.) were used at the following final
concentrations: cephalexin, 10 mg/ml; gentamicin, 20 mg/ml; ampicillin, 30 mg/ml;
kanamycin, 50 mg/ml; tetracycline, 10 mg/ml; streptomycin, 20 mg/ml; and chlor-
amphenicol, 50 mg/ml. Escherichia coli strains were grown on Luria-Bertani (LB)
agar or in Luria-Bertani broth (26) supplemented, when appropriate, with am-
picillin (100 mg/ml) or gentamicin (20 mg/ml). E. coli DH5a (Stratagene, La Jolla,
Calif.) was used in all of the cloning steps, and E. coli SM10 (28) was used to
mobilize plasmids into B. pertussis.
Electroporation. Cells were grown in SS medium to mid-exponential phase,
chilled on ice for 10 min, and harvested by centrifugation (7,000 3 g, 4°C). After
two washes with ice-cold H2O, cells were resuspended in ice-cold H2O and the
concentration was adjusted so that the optical density at 600 nm was 5.0. Forty
microliters of this suspension was mixed with 1 mg of desalted plasmid DNA in
a prechilled electroporation cuvette (Bio-Rad). After application of the electric
pulse (25 mF, 2,500 V, 200 V; Bio-Rad Gene Pulser), cells were allowed to
outgrow in 1 ml of SS medium for 60 min at 37°C, concentrated by centrifuga-
tion, and plated on selective BG-blood agar.
Conjugation and allelic exchange. Matings were performed as previously de-
scribed (19). To counterselect against the donor strain, mating products were
plated on BG blood agar supplemented with a colicin B-enriched bacterial lysate
(approximately 5 mg of total protein per ml), which was prepared from the
colicin-producing E. coli strain DM1187(pCLB1) (a gift of Theresa Finn) as
previously described (7). For allelic exchange, the sacBR-based system was used
(1). Bacteria that had undergone a second recombination event resulting in loss
of plasmid sequences were selected on BG-blood agar containing 10% sucrose.
Construction of B. pertussis phase-locked and deletion mutants. A Bvg1
phase-locked derivative of strain 18323 was constructed as follows. Suicide plas-
mid pJM503, which contains a 2.3-kb SfiI fragment of 9bvgS9 containing the
bvgS-C3 mutation (23), was electroporated into strain 18323, and cointegrates
were selected on BG-blood agar supplemented with gentamicin. As expected,
cointegrates grew as large, flat, nonhemolytic colonies characteristic of the Bvg2
phase. Although pJM503 contains the rpsL gene, encoding streptomycin sensi-
tivity (Sms), this selection was not used because the 18323 parental strain is Sms.
Instead, two cointegrates were picked, grown without antibiotic selection, and
plated on BG agar containing 40 mM nicotinic acid and 15 mM MgSO4 to screen
phenotypically for colonies in which a second recombination event resulting in
loss of plasmid sequences had occurred. Small, domed, hemolytic colonies on this
medium, indicative of the Bvgc phenotype, were characterized further. These
colonies were gentamicin sensitive (Gms), indicating that they had indeed lost
plasmid pJM503. One was named SC3 and was used in all subsequent analyses.
A Bvg2 derivative of 18323 was constructed by creating a disruption in bvgS by
using plasmid pGMT74. pGMT74 is a suicide plasmid containing a 1.9-kb EcoRI-
SnaBI internal bvgS fragment. Integration of this plasmid into strain 18323 disrupts
bvgS, rendering the strain phenotypically Bvg2 under all growth conditions.
Integration of pGMT74 is not expected to have polar effects, as the gene 39 to
bvgAS, bvgR, is transcribed in the orientation opposite to that for bvgAS (refer-
ence 21 and our unpublished data). A Bvg2 derivative of SK6 (DS1-SK6) was
constructed by mobilization of pGMT74 into SK6.
Strain D6, containing an in-frame deletion in vrg6, was constructed as follows.
An 818-bp EcoRI fragment containing vrg6 was amplified from the 18323 chro-
mosome by PCR with oligonucleotides predicted to anneal at positions 1 (59-G
AATTCCGTCTGCTGAACCAGA-39) and 792 (39) (59-GAATTCGCATAAC
GGCTGGTGGAAGG-39) of the published sequence (6). The PCR product was
digested with EcoRI and cloned into EcoRI-digested pUC19 to create pGMT42.
To generate an in-frame deletion in vrg6, pGMT42 was digested with EcoRV and
NcoI, filled in with Klenow fragment, and religated, resulting in the deletion of
0.2 kb of DNA corresponding to approximately 70% of vrg6. The deletion
junction was confirmed to have occurred as intended by DNA sequence analysis.
Sequences at the 59 end of vrg6 reported to be essential for maintaining Bvg-
dependent regulation were left intact to avoid polar effects on downstream genes.
The 0.6-kb EcoRI fragment was then cloned into plasmid pEG25 (19), and the
resulting plasmid, containing the sacBR cassette, was used to transfer the vrg6
deletion to the chromosome of strain 18323. PCR and Southern blot analyses
confirmed that D6 was constructed as intended.
To construct an 18323 derivative containing an in-frame deletion in bvgR, a
2.5-kb BclI-EcoRV fragment containing the bvgR locus from B. pertussis 338 was
cloned into FspI-BamHI-digested pACYC177. The resulting plasmid was digest-
TABLE 1. Strains used in this study
Species and strain Characteristics Source or reference
B. pertussis
18323 (ATCC 9797) Wild type, Sms ATCC
SK6 vrg6::TnphoA Smr; original mutant 6
NSK6 vrg6::TnphoA Smr; 18323 transductant This work
SC3 bvgS-C3 Sms This work
D6 Dvrg6 Sms; in-frame deletion in vrg6 This work
DR DbvgR Sms; in-frame deletion in bvgR This work
DS1 bvgS::pGMT74 Sms; bvgS disruption This work
SC3-SK6 bvgS-C3 vrg6::TnphoA Smr; SC3 transductant This work
DR-SK6 DbvgR vrg6::TnphoA Smr; DR transductant This work
DS1-SK6 bvgS::pGMT74 vrg6::TnphoA Smr This work
BP121 vrg6::TnphoA9-9tnpR-res-tet-res-9vrg6 Smr This work
BP147 vrg6::TnphoA9-9tnpR-res-tet-res-vrg6 Smr This work
NBP121 vrg6::TnphoA9-9tnpR-res-tet-res-9vrg6 Smr; 18323 transductant This work
NBP147 vrg6::TnphoA9-9tnpR-res-tet-res-vrg6 Smr; 18323 transductant This work
E. coli
DH5a F2 hsdR17 supE44 thi-1 recA1 gyrA relA1 D(argF-lac) U169 f80dlacZDM15 Bethesda Research Laboratories
SM10 RP4-2-TcMu Kmr 28
DM1187(pCLB1) Colicin B-expressing strain Theresa Finn
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ed with FspI and ScaI and religated, resulting in the deletion of 425 bp of DNA
containing approximately 66% of bvgR. The deletion junction was confirmed to
result in an in-frame deletion by DNA sequence analysis. The resulting DbvgR
allele, contained on a 0.9-kb SalI-XhoI fragment, was then cloned into plasmid
pEG25 (19) and used to transfer the DbvgR allele to the chromosome of strain
18323. Southern blot analysis confirmed that DR was constructed as intended.
Construction of B. pertussis strains containing resolvase reporters of vrg6 ex-
pression. Strains BP121 and BP147, containing tnpR-res-tet-res cassettes for assess-
ing vrg6 transcription, were constructed as follows. A plasmid derivative of pSS1129
containing a 9tnpR-res-tet-res-neo cassette (8) flanked by phoA sequences at the 59
end and vrg6 39 sequences at the 39 end was used to transfer the 9tnpR-res-tet-
res-neo cassette to the chromosome of SK6 by allelic exchange, resulting in the
construction of BP121. In this strain, transcription of vrg6 drives expression of the
promoterless 9tnpR. The tnpR gene product mediates site-specific recombination
between the res sequences, resulting in the excision of the tet gene. vrg6 expres-
sion therefore results in the loss of tetracycline resistance (Tcr). Strain BP147 is
identical to BP121 except that a complete copy of vrg6 was provided at the 39 end
of the construct such that this strain contains a wild-type copy of vrg6. Southern
blots confirmed that BP121 and BP147 were constructed as intended.
Construction of B. pertussis strains by generalized transduction. A Bordetella-
specific bacteriophage capable of mediating generalized transduction was re-
cently discovered in our laboratory (18a). This phage, designated BP3c, was used
to transduce the vrg6-phoA fusion and linked sequences from B. pertussis SK6,
BP121, and BP147 to the wild-type strain 18323 to create NSK6, NBP121, and
NBP147, respectively. SK6, BP121, and BP147 are kanamycin resistant (Kmr)
due to the Kmr gene contained on the TnphoA element. They are also Smr. The
basis for their being Smr is unknown, as they are derivatives of 18323, which is
Sms. Transductants were selected on BG-blood agar containing kanamycin. Un-
expectedly, all transductants were found to be Smr, suggesting that the Kmr gene
contained on TnphoA also confers Smr to B. pertussis. Southern blot analysis
indicated that the genomic organizations of the vrg6-phoA regions were indistin-
guishable between SK6, BP121, and BP147 and NSK6, NBP121, and NBP147,
respectively. This transduction protocol was also used to transfer the vrg6-phoA
fusion from SK6 to SC3 and DR, creating SC3-SK6 and DR-SK6, respectively.
Details of BP3c-mediated generalized transduction will be described elsewhere.
Western immunoblotting. Sodium dodecyl sulfate (SDS)-polyacrylamide gel
electrophoresis was performed by the method of Laemmli (18). B. pertussis
whole-cell lysates solubilized in sample buffer (60 mM Tris, 2% SDS, 10%
glycerol, 0.005% bromophenol blue, 0.1 M dithiothreitol, pH 6.8) were stacked
in a 5% polyacrylamide gel and separated in a 4 to 12% acrylamide-bisacrylam-
ide (29:1) linear gradient gel. Proteins were transferred to Immobilon-P mem-
branes (Millipore Corp., Bedford, Mass.) and probed with a 1:2,500 dilution of
serum from a patient recovering from whooping cough (a gift of James Cherry,
UCLA Department of Pediatrics) or a 1:10 dilution of anti-VraB monoclonal
antibody (a gift of Mark Peppler [31]). Sheep anti-human or sheep anti-mouse
horseradish peroxidase-conjugated secondary antibodies (Amersham Interna-
tional, Little Chalfont, United Kingdom) were used at a dilution of 1:5,000. The
immunocomplexes were detected by using an enhanced chemiluminescence as-
say (Amersham) according to the manufacturer’s directions.
Experimental animals. Three-week-old, Bordetella-free, female BALB/cAnNCR
mice obtained from Charles River Laboratories were used in this study. Inocula
were prepared by growing B. pertussis strains on BG-blood agar for 3 days at 37°C
and then suspending the harvested cells in sterile phosphate-buffered saline
(PBS). Mice were inoculated intranasally with 50 ml of PBS containing 104 CFU
while the animals were slightly anesthetized with halothane. At the indicated
times postinoculation, mice were sacrificed by halothane inhalation, the chest
cavity was opened, and blood was obtained by cardiac puncture. One centimeter
of mid-trachea and the right lung lobes were removed aseptically, homogenized
in PBS, diluted, and plated on BG-blood agar. The nasal cavity was opened, and
the nasal septum and adjacent turbinates were removed, homogenized in PBS,
diluted, and plated. Animal protocols were approved by the University of Cali-
fornia, Los Angeles, Animal Research Committee (ARC protocol 94-043). Sta-
tistical significance was determined by using a paired t test (P # 0.05).
Alkaline phosphatase activity assays. Alkaline phosphatase activity was mea-
sured by a published method (22).
Resolution of res-tet-res sequences. To determine the resolution frequencies of
res-tet-res sequences in NBP121 and NBP147 in vitro, NBP121 and NBP147 were
grown on BG-blood agar with or without 5 mM nicotinic acid and 20 mM MgSO4
for 72 h at 37°C, and cells were harvested and plated on BG-blood agar without
tetracycline and then replica plated onto BG-blood agar with and without tet-
racycline. Percent resolution was defined as number of Tcs colonies/total number
of colonies. The percentage of Tcs colonies was also determined by individually
patching colonies onto BG-blood agar with and without tetracycline. To deter-
mine the resolution frequency following in vivo growth, colonies recovered from
the respiratory tracts of mice at 12 and 20 days postinoculation were plated onto
BG-blood agar without tetracycline and then replica plated onto BG-blood agar
with and without tetracycline. Individual colonies were also patched onto agar
with and without tetracycline to confirm these data. For both the in vitro and in
vivo assays, the inocula were prepared by growing cells on BG-blood agar con-
taining tetracycline.
RESULTS AND DISCUSSION
Construction and in vitro characterization of phase-locked
B. pertussis strains. Strain 18323 (Table 1) is the American
Type Culture Collection (ATCC) type strain for B. pertussis.
Although it has been recognized for some time that this strain
is not typical of clinical B. pertussis isolates (3, 14, 24), it was
chosen for this study so that our results could be directly
compared with those of Beattie et al., from which it was con-
cluded that the Bvg2 phase gene, vrg6, was required for viru-
lence (6). 18323 is also the strain used in the intracerebral
challenge test to assess the potencies of whole-cell pertussis
vaccines, and it has been used extensively in an aerosol model
of B. pertussis respiratory infection (27). 18323 is phenotypi-
cally wild type for Bvg. It forms small, domed, hemolytic col-
onies on BG-blood agar after 4 days of incubation at 37°C
(nonmodulating or Bvg1 phase conditions) and large, flat,
nonhemolytic colonies on BG-blood agar supplemented with
20 mM MgSO4 and 5 mM nicotinic acid (modulating or Bvg
2
phase conditions). When grown under nonmodulating condi-
tions, 18323 expresses Bvg1 phase-specific antigens which can
be detected by Western blotting with sera from children re-
covering from pertussis (Fig. 1A). It is interesting that the vast
majority of antigens detected by using convalescent-phase sera
are Bvg1 phase specific. When 18323 is grown under modu-
lating conditions, these Bvg1 phase antigens are not expressed
(Fig. 1A), and instead Bvg-repressed factors, including VraB
(Fig. 1B) and vrg6 (Fig. 2), are expressed.
We constructed a Bvg1 phase-locked derivative of 18323 by
transferring the bvgS-C3 mutation to the chromosome by al-
lelic exchange (1, 23) (see Materials and Methods). The bvgS-
C3 allele, a single nucleotide change resulting in an arginine-
to-histidine substitution at amino acid position 570 in the link-
er region of BvgS, was originally isolated from and character-
ized for B. pertussis BP370 (23). bvgS-C3 also confers a Bvg
constitutive (Bvgc) phenotype to B. bronchiseptica (11). Strain
SC3 (18323 bvgS-C3 [Table 1]) formed small, domed, hemo-
lytic colonies on BG-blood agar with or without the addition of
20 mM MgSO4 and 5 mM nicotinic acid. Its antigenic profile
was similarly insensitive to modulating conditions; it constitu-
tively expressed Bvg1 phase antigens recognized by convales-
cent-phase serum (Fig. 1A) as well as filamentous hemagglu-
tinin, fimbriae, and pertactin (data not shown) and did not
express Bvg-repressed factors such as VraB (Fig. 1B) or vrg6
(Fig. 2) even under modulating conditions.
To create a Bvg2 phase-locked derivative of 18323, we dis-
rupted the bvgS gene with plasmid pGMT74, a suicide plasmid
containing an internal bvgS fragment (Table 1). DS1 (18323::
pGMT74 [Table 1]) forms large, flat, nonhemolytic colonies
under both modulating and nonmodulating conditions, never
expresses Bvg1 phase factors (Fig. 1A), and constitutively ex-
presses VraB (Fig. 1B) and vrg6 (Fig. 2).
The Bvg1 phase of B. pertussis 18323 is necessary and suffi-
cient for respiratory infection in mice. To determine if modu-
lation to the Bvg2 phase is important for B. pertussis respira-
tory infection, we compared isogenic wild-type and phase-locked
strains in a mouse model. Groups of 3-week-old BALB/c mice
were inoculated intranasally with 50 ml of PBS containing 5 3
104 CFU of either 18323 or its mutant derivatives. Animals
were sacrificed at day 0 (to estimate the number of CFU de-
livered to each site in the respiratory tract) and days 11, 26, and
35 postinoculation. For both 18323 and SC3, the numbers of
CFU recovered from the nasal cavity, trachea, and lungs were
increased at day 11 compared to day 0 and then decreased at
day 26 and further still at day 35 (Fig. 3). There was no signif-
icant difference between the number of CFU recovered from
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18323- and SC3-inoculated mice at any site at any time point.
In all cases, bacteria recovered from each site were phenotyp-
ically identical to the inoculum. In contrast, DS1 was not re-
covered from any site from any animal at day 6 postinocula-
tion, confirming previous reports that Bvg2 mutants are unable
to colonize the respiratory tract (34, 35).
Since strains 18323 and SC3 were indistinguishable in their
ability to colonize the nasal cavity, trachea, and lungs, we con-
clude that the Bvg1 phase is necessary and sufficient for respi-
ratory infection by B. pertussis. We cannot conclude from these
data, however, that wild-type B. pertussis does not modulate to
the Bvg2 phase in vivo. To address this issue, we examined the
antibody profile generated in response to B. pertussis infection.
Sera from both 18323- and SC3-infected mice showed weak
reactivity against Bvg1 phase antigens and antigens common
to both the Bvg1 and Bvg2 phase but showed no reactivity
against Bvg2 phase-specific antigens (data not shown). Simi-
larly, sera from children recovering from pertussis contain high
titers of antibody against Bvg1 phase factors and factors com-
mon to both phases but not Bvg2 phase factors (Fig. 1A).
These results indicate that either the transition to the Bvg2
phase does not occur in vivo or Bvg2 phase factors are non-
antigenic. These results are exactly the same as those obtained
with wild-type and phase-locked B. bronchiseptica strains in
rabbits and rats (1, 11).
Bvg-mediated repression of gene expression is required for
efficient tracheal colonization. The bvgR locus is involved in
Bvg1 phase repression of at least two vrg genes, vrg6 and vrg73
(21), as well as the VraB antigen (30). To further characterize
the contribution of BvgR to regulation of vrg gene expression,
we constructed a mutant derivative of strain 18323 containing
an in-frame deletion in bvgR (see Materials and Methods)
(Table 1). The colony morphologies displayed by DR (18323
DbvgR) under modulating and nonmodulating conditions were
indistinguishable from those of 18323. Similarly, the DbvgR
strain was unaltered in its ability to express Bvg1 phase anti-
gens, as determined by Western blot analysis with convales-
cent-phase serum (Fig. 1A). VraB expression, however, was
FIG. 1. Western blot analysis of the antigenic profiles of wild-type and mutant B. pertussis strains. Whole-cell lysates of the indicated strains grown under
nonmodulating (Bvg1 phase) conditions or modulating (Bvg2 phase) conditions were separated on an SDS–4 to 12% gradient polyacrylamide gel, transferred to
polyvinylidene difluoride, and probed with serum from a child recovering from pertussis (A) or anti-VraB antibody (B). The positions of the molecular weight markers
(in thousands) are shown at the left. WT, wild type.
FIG. 2. Effect of BvgAS and BvgR on vrg6 expression. Wild-type and mutant
B. pertussis strains containing vrg6-phoA fusions were grown on BG-blood agar
under nonmodulating (open bars) or modulating (shaded bars) conditions and
suspended in assay buffer, and alkaline phosphatase activity was measured.
Values are the means and standard errors for at least three independent assays
performed in duplicate.
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partially derepressed in the bvgR mutant grown under non-
modulating conditions (Fig. 1B), as was vrg6 expression as
determined by measuring alkaline phosphatase activity in a
strain containing a vrg6::TnphoA fusion (Fig. 2; also see be-
low). These results are consistent with previous reports in
which the involvement of BvgR in repression of vrg6 and VraB
was first described (21, 30) and suggest that an additional form
of Bvg-dependent negative regulation exists. Since deletion of
bvgR results in the inappropriate Bvg1 phase expression of
genes that are normally not expressed in this phase, the DbvgR
strain can be classified as an ectopic expression mutant.
To assess the importance of BvgR-mediated repression of
gene expression during infection, we compared the DbvgR
strain with strain 18323 in our mouse model. The numbers of
DR CFU recovered from the nasal cavity, trachea, and lungs at
day 11 postinoculation were decreased compared to those for
18323. This moderate difference was statistically significant in
the trachea and lungs (Fig. 3). Ectopic Bvg1 phase expression
of at least one class of vrg genes therefore inhibits tracheal and
lung colonization, demonstrating the importance of BvgR-me-
diated repression, and hence BvgAS-mediated repression, of
gene expression in vivo. This result is analogous to our previ-
ous report showing that ectopic expression of motility in the
Bvg1 phase of B. bronchiseptica is detrimental to the develop-
ment of respiratory infection in rats (1).
Construction and in vitro characterization of vrg6 mutants.
B. pertussis SK6 is a derivative of strain 18323 containing a
TnphoA insertion in the vrg6 locus (16). This strain is Smr and
Kmr due to the transposon (see Materials and Methods). SK6
has been shown to be defective for tracheal and lung coloni-
zation in mice (6). To determine if the virulence defect of SK6
was in fact due to the vrg6 transposon insertion, we constructed
two new mutants. First, we used a recently identified Borde-
tella-specific bacteriophage (18a) to transduce the vrg6::TnphoA
mutation into wild-type 18323. The resulting strain, NSK6 (Ta-
ble 1), is isogenic with 18323 except for the transposon inser-
tion into vrg6. Like SK6, NSK6 is Smr and Kmr due to the
transposon. To specifically examine vrg6 gene function in the
absence of polar effects, we also constructed an 18323 deriva-
tive containing an in-frame deletion in vrg6 (Table 1) (see
Materials and Methods). Like 18323, this strain (D6) is Sms.
The mini-TnphoA element in SK6 inserted into vrg6 such
that a vrg6-phoA translational fusion was created, allowing
alkaline phosphatase activity to serve as an indicator of vrg6
expression (16). In both SK6 and NSK6, alkaline phosphatase
activity was about 10-fold higher when the strains were grown
under modulating conditions compared to nonmodulating con-
ditions (Fig. 2), consistent with previous reports (5, 16). To
confirm the roles of BvgAS and BvgR in vrg6 repression, we
transduced the vrg6::TnphoA allele into SC3, the Bvg1 phase-
locked strain, and DR, the DbvgR strain, creating SC3-SK6 and
DR-SK6, respectively. Integration of pGMT74 into NSK6 cre-
ated DS1-NSK6, a Bvg2 mutant containing the vrg6-phoA fu-
sion. vrg6-phoA expression was constitutively low in SC3-SK6
and high in DS1-NSK6 regardless of growth conditions (Fig.
2), confirming that BvgAS mediates repression, either directly
or indirectly, of vrg6 gene expression under Bvg1 phase con-
ditions. vrg6-phoA expression was partially derepressed in DR-
SK6 grown under nonmodulating conditions compared to in
DS1-NSK6 and compared to in DR-SK6 grown under mod-
ulating conditions. This result confirms that of Merkel and
Stibitz (21) and suggests that while BvgR plays a role in
BvgAS-mediated repression of vrg6, it may not account for full
repression of vrg6 under nonmodulating conditions.
vrg6 is not required for respiratory infection. We compared
the various vrg6 mutant strains with strain 18323 in our murine
model of respiratory infection. Consistent with the results of
Beattie et al. (6), recovery of SK6 from all sites in the respi-
ratory tract was dramatically reduced compared to that of
18323 at day 11 postinoculation, and SK6 was not recovered
from the trachea or lungs on day 26 or 35 postinoculation (Fig.
4). In contrast, the numbers of CFU of NSK6 and D6 were
statistically indistinguishable from those of 18323 at all sites
and time points (Fig. 4). These results demonstrate first and
FIG. 3. Time course of respiratory tract colonization by wild-type and mutant
B. pertussis strains. (A) Schematic of strains used in this experiment. Bvg1 phase
bacteria normally express adhesins (solid bars) and toxins (solid circles), while
Bvg2 phase bacteria express vrg6 (open bars) and other BvgR-regulated factors
(open circles) and possibly other, non-BvgR-regulated vrg genes (not shown). wt,
wild type. (B) Respiratory tract colonization. Mice were inoculated intranasally
with 50 ml of PBS containing 5 3 104 CFU of the indicated strains, and the
numbers of CFU present in the nasal cavity, trachea, and lungs were determined
at the indicated times postinoculation. Each symbol represents the mean number
of CFU recovered from three animals. Error bars represent 61 standard error.
Dashed lines indicate the lower limit of detection. p, P , 0.05.
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foremost that vrg6 is not required for respiratory infection by
B. pertussis. Since polar effects present in SK6 would also be
present in NSK6, the colonization defect of SK6 is also not due
to polar effects on genes downstream of vrg6. Additionally,
since NSK6, which is Smr, is not defective for colonization, the
colonization defect of SK6 is not due to the fact that it is Smr.
Taken together, these results indicate that the SK6 virulence
defect observed here and by Beattie et al. (6) must be due to
a mutation in a locus other than vrg6. In vitro comparison of
SK6 with 18323 revealed no obvious differences in colony mor-
phology or antigenic profile, suggesting that SK6 may contain
a mutation in a previously unrecognized virulence factor.
Whatever the mutation, it has a profound effect on virulence.
vrg6 expression is not induced in vivo. Comparison of SK6,
NSK6, and D6 with 18323 indicates that vrg6 expression is not
required during infection in our murine model. These results
do not, however, rule out the possibility that vrg6 expression is
induced in vivo. To investigate this possibility, we constructed
strains containing recombinase gene fusions as reporters of
vrg6 expression (Fig. 5). This reporter system is based on site-
specific recombination in response to tnpR (resolvase) gene
expression (8). NBP121 and NBP147 are SK6 derivatives in
which a promoterless resolvase gene (9tnpR) is inserted down-
stream of vrg6::phoA followed by res-tet-res sequences. The res
sequences are the targets of the resolvase, and tet confers Tcr.
Expression of vrg6 results in expression of the resolvase, exci-
sion of the res-tet-res cassette, and conversion of the strain from
Tcr to Tcs. Approximately 7% of the colonies tested following
4 days of growth on BG-blood agar at 37°C (Bvg1 phase
conditions) were Tcs, while almost 90% of the colonies tested
following growth on BG-blood agar containing 5 mM nicotinic
acid and 20 mM MgSO4 (Bvg
2 phase conditions) were Tcs
(Table 2). Since the levels of vrg6 expression in NSK6 grown on
BG-blood agar in the absence and presence of 5 mM nicotinic
acid and 20 mM MgSO4 are similar to those in SC3-SK6 and
DS1-SK6, respectively (Fig. 2), we conclude that 7 and 90%
resolutions reflect the levels of vrg6 expression under non-
modulating and modulating conditions, respectively. To deter-
mine if vrg6 expression is induced in vivo, we inoculated groups
of 3-week-old BALB/c mice with 5 3 104 CFU of NBP121 and
determined the ratio of Tcs to Tcr CFU recovered from the
nasal cavity, trachea, and lungs on days 12 and 20 postinocu-
lation. An average of 17% of all colonies recovered from all
sites in the respiratory tract on any day were Tcs (Table 2).
These results indicate that vrg6 expression is low in vivo, only
slightly greater than levels observed following in vitro growth
under nonmodulating conditions, suggesting that modulation
to the Bvg2 phase may not occur in vivo.
Implications. We have shown, by using phase-locked and
ectopic expression mutants, that the Bvg1 phase of B. pertussis
is necessary and sufficient for respiratory tract colonization and
that inappropriate expression of Bvg2 phase factors in the
Bvg1 phase decreases colonization efficiency. We further dem-
onstrated that vrg6 is not required for virulence. These data
repudiate an in vivo role for the Bvg2 phase of B. pertussis and
suggest that BvgAS may in fact perform the same function(s)
FIG. 4. Time course of respiratory tract colonization by the wild-type strain
and vrg6 mutants. Mice were inoculated intranasally with 50 ml of PBS containing
5 3 104 CFU of strain 18323 (E), SK6 (), NSK6 (), or D6 (F) (Table 1), and
the numbers of CFU present in the nasal cavity, trachea, and lungs were deter-
mined at the indicated times postinoculation. Each symbol represents the mean
number of CFU recovered from three animals. Error bars represent 61 standard
error. Dashed lines indicate the lower limit of detection. p, P , 0.05.
FIG. 5. Use of a resolvase reporter fusion to determine vrg6 expression in
vivo. A 9tnpR-res-tet-res-neo cassette was inserted into the TnphoA present in
SK6. tnpR expression is under the control of the vrg6 promoter, and therefore
excision of res-tet-res sequences reflects vrg6 expression. neo contains a Kmr gene.
TABLE 2. Resolution of res-tet-res sequences following
growth in vitro and in vivoa
Strain or
site
% Tcs colonies (mean 6 SE) after growth:
In vitrob In vivoc
Bvg1 phase
conditions
Bvg2 phase
conditions Day 12 Day 20
NBP121 7.4 6 4.5 89.6 6 5.2
NBP147 7.6 6 3.4 86.9 6 4.4
Nasal cavity 14 6 6.4 16 6 5.8
Trachea 17 6 4.3 18 6 7.2
Lungs 19 6 5.5 16 6 6.7
a See Fig. 5.
b Strains were grown on BG-blood agar with or without the addition of 5 mM
nicotinic acid and 5 mM MgSO4 for 72 h. Cells were then harvested and plated,
and the percentage of Tcs resolvants was determined.
c Mice were inoculated with NBP121 grown on plates containing tetracycline.
At 12 and 20 days postinoculation, the percentages of Tcs colonies recovered
from the nose, trachea, and lungs were determined.
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in B. pertussis and B. bronchiseptica. If this suggestion is true,
how do we account for differences in Bvg2 phase phenotypes
and for the fact that B. pertussis is thought to be incapable of
surviving outside its human host? We recently reported the
discovery of Bvg intermediate (Bvgi) phase antigens in B. bron-
chiseptica and put forth the hypothesis that the Bvgi phase may
be important for aerosol transmission while the Bvg2 phase
may be important for transmission via an environmental res-
ervoir (12). Characterization of the Bvgi phase of B. pertussis
has revealed cross-reacting Bvgi phase antigens, and sera from
children recovering from pertussis contain antibodies that rec-
ognize some of these antigens (19a). These data suggest that
the Bvgi phase of B. pertussis is expressed in vivo. We propose,
therefore, that BvgAS may function to distinguish sites within
and outside the mammalian respiratory tract in both B. pertus-
sis and B. bronchiseptica. Since B. pertussis appears to be con-
fined to transmission by the aerosol route, the role of BvgAS in
this species may be primarily to mediate the transition between
the Bvg1 and Bvgi phases, allowing B. pertussis to alternate
between a virulent phase and a transmission-competent phase.
In B. bronchiseptica, the role of BvgAS may be extended to
include the transition to the Bvg2 phase, which may allow this
organism to survive in environmental reservoirs. We are cur-
rently characterizing Bvgi and Bvg2 phase phenotypes in
B. pertussis and B. bronchiseptica and their potential roles in
transmission to test these hypotheses.
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